A breakthrough in early cancer detection
Our technology is supported by evidence from our population-scale clinical study program, believed to be the largest of its kind.
The Circulating Cell-free Genome Atlas (CCGA) Study
An observational, longitudinal study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study is being used to discover, train, and validate GRAIL’s products.
A validation study of Galleri’s clinical and economic performance in the United Kingdom’s National Health System
A prospective, interventional, multi-center study evaluating an earlier version of Galleri in clinical practice. PATHFINDER is our first study that returns results to physicians and participants to evaluate how these test results affect diagnostic and care pathways in a screening population.
PATHFINDER 2 Study
This is a prospective, multi-center interventional study of the Galleri multi-cancer early detection test with return of test results for participants enrolled through healthcare systems in North America.
An observational study of patients administered the Galleri test.
A prospective, observational, longitudinal, cohort study that enrolled approximately 100,000 women to help validate Galleri in an asymptomatic and intended use population.
A prospective, observational, longitudinal, cohort study in London, United Kingdom. The study is designed to enroll approximately 13,000 men and women who do not have a cancer diagnosis at the time of enrollment.
Transparency and sharing our learnings with the broader clinical and scientific community is of the utmost importance. This is why we publish manuscripts in a variety of peer-reviewed journals and present at medical conferences around the world to communicate our findings.
Criteria for Evaluating Multi-cancer Early Detection Tests
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set
Health State Utility Values by Cancer Stage: A Systematic Literature Review
Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
A Comprehensive Characterization of the Cell-free Transcriptome Reveals Tissue and Subtype-specific Biomarkers for Cancer Detection
Multi-cancer early detection: a new paradigm for reducing cancer-specific and all-cause mortality
Modeled reductions in late-stage cancer with a multi-cancer early detection test
Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection
NextIndependent medical education
GRAIL is committed to helping fund innovative and impactful education to meet the needs of practicing healthcare professionals and the communities of care that they manage within our areas of interest.
Sign Up Successful!
Externally sponsored research
GRAIL encourages the submission of scientifically sound and innovative research proposals.